Immix Biopharma Inc. (IMMX)
Immix Biopharma Statistics
Share Statistics
Immix Biopharma has 27.51M shares outstanding. The number of shares has increased by 7.73% in one year.
| Shares Outstanding | 27.51M |
| Shares Change (YoY) | 7.73% |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | 13.92% |
| Shares Floating | 16.38M |
| Failed to Deliver (FTD) Shares | 5.46K |
| FTD / Avg. Volume | 4.05% |
Short Selling Information
The latest short interest is 434.94K, so 1.58% of the outstanding shares have been sold short.
| Short Interest | 434.94K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 2.94 |
Valuation Ratios
The PE ratio is -7.78 and the forward PE ratio is -2.86. Immix Biopharma's PEG ratio is -0.18.
| PE Ratio | -7.78 |
| Forward PE | -2.86 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 7.31 |
| P/FCF Ratio | -10.5 |
| PEG Ratio | -0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immix Biopharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.
| Current Ratio | 5.32 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.94% and return on capital (ROIC) is -99.78%.
| Return on Equity (ROE) | -0.94% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -99.78% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.1M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 26.41K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -50% in the last 52 weeks. The beta is 0.23, so Immix Biopharma's price volatility has been higher than the market average.
| Beta | 0.23 |
| 52-Week Price Change | -50% |
| 50-Day Moving Average | 2.03 |
| 200-Day Moving Average | 1.97 |
| Relative Strength Index (RSI) | 43.27 |
| Average Volume (20 Days) | 134.65K |
Income Statement
| Revenue | n/a |
| Gross Profit | -5.47K |
| Operating Income | -16.14M |
| Net Income | -15.43M |
| EBITDA | -16.14M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
The company has 17.51M in cash and 0 in debt, giving a net cash position of 17.51M.
| Cash & Cash Equivalents | 17.51M |
| Total Debt | 0 |
| Net Cash | 17.51M |
| Retained Earnings | -53.41M |
| Total Assets | 25.14M |
| Working Capital | 16.19M |
Cash Flow
In the last 12 months, operating cash flow was -11.37M and capital expenditures -52.09K, giving a free cash flow of -11.42M.
| Operating Cash Flow | -11.37M |
| Capital Expenditures | -52.09K |
| Free Cash Flow | -11.42M |
| FCF Per Share | -0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IMMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -50.86% |
| FCF Yield | -23.77% |
Analyst Forecast
The average price target for IMMX is $7, which is 300% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 300% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 2 |